GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » EV-to-EBIT

Jafron Biomedical Co (SZSE:300529) EV-to-EBIT : 32.03 (As of May. 18, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Jafron Biomedical Co's Enterprise Value is ¥22,027 Mil. Jafron Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥688 Mil. Therefore, Jafron Biomedical Co's EV-to-EBIT for today is 32.03.

The historical rank and industry rank for Jafron Biomedical Co's EV-to-EBIT or its related term are showing as below:

SZSE:300529' s EV-to-EBIT Range Over the Past 10 Years
Min: 17.01   Med: 42.7   Max: 122.05
Current: 31.88

During the past 13 years, the highest EV-to-EBIT of Jafron Biomedical Co was 122.05. The lowest was 17.01. And the median was 42.70.

SZSE:300529's EV-to-EBIT is ranked worse than
70.15% of 459 companies
in the Medical Devices & Instruments industry
Industry Median: 20.41 vs SZSE:300529: 31.88

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Jafron Biomedical Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥16,621 Mil. Jafron Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥688 Mil. Jafron Biomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.14%.


Jafron Biomedical Co EV-to-EBIT Historical Data

The historical data trend for Jafron Biomedical Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co EV-to-EBIT Chart

Jafron Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.95 51.94 29.24 22.56 29.24

Jafron Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.66 33.91 30.69 29.24 24.17

Competitive Comparison of Jafron Biomedical Co's EV-to-EBIT

For the Medical Devices subindustry, Jafron Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jafron Biomedical Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jafron Biomedical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jafron Biomedical Co's EV-to-EBIT falls into.



Jafron Biomedical Co EV-to-EBIT Calculation

Jafron Biomedical Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=22027.483/687.711
=32.03

Jafron Biomedical Co's current Enterprise Value is ¥22,027 Mil.
Jafron Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥688 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jafron Biomedical Co  (SZSE:300529) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Jafron Biomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=687.711/16621.41765
=4.14 %

Jafron Biomedical Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥16,621 Mil.
Jafron Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥688 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jafron Biomedical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Jafron Biomedical Co (SZSE:300529) Business Description

Traded in Other Exchanges
N/A
Address
No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines